In 2020, the Crohn ́s & Colitis Foundation of America recommended that patients with Inflammatory Bowel Disease (IBD) that develop COVID-19 stop the anti-TNF administration (biologics or biosimilars) until they recover. Here, TNF is linked to inflammatory bowel disease.